Ozempic For Weight Loss: What it is, How it works, Uses, Benefits, Dosage, and Safety Guide

Ozempic is a once-weekly injectable prescription medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved by the U.S. Food and Drug Administration for adults with type 2 diabetes to improve blood glucose control, to reduce the risk of major adverse cardiovascular events in those with known heart disease, and to reduce the risk of worsening kidney disease and cardiovascular death in those with chronic kidney disease. Weight loss is an effect of treatment, not its indication.

Ozempic contains semaglutide, a long-acting synthetic analogue of the naturally occurring incretin hormone GLP-1. Naturally, incretin hormones are released in the gut after meals to help manage blood sugar levels. Semaglutide activates GLP-1 receptors, producing complementary effects on glycaemic control, appetite, and cardiovascular risk.

In the pancreas, semaglutide improves glucose-dependent insulin secretion from beta cells and suppresses glucagon release from alpha cells, which helps in lowering both fasting and post-meal glucose.

In the GI tract, semaglutide slows gastric emptying, which helps prevent post-meal glucose spikes and gives early satiety. In the central nervous system, GLP-1 receptor activation reduces hunger and food intake, which accounts for the consistent weight reduction observed during treatment.

The cardiovascular and kidney benefits seen in outcome trials reflect a combination of metabolic improvement, blood pressure reduction, anti-inflammatory effects, and direct vascular and renal effects beyond glucose-lowering alone. Ozempic is administered using a pre-filled multi-dose pen and is initiated at a low dose with structured escalation to an effective maintenance dose once weekly.

Ozempic has three approved uses in adults with type 2 diabetes mellitus.

• As an adjunct to diet and exercise to improve glycaemic control.
• To reduce the risk of major adverse cardiovascular events, specifically cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in adults with type 2 diabetes and established cardiovascular disease.
• To reduce the risk of sustained worsening of kidney function, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Ozempic is not approved for type 1 diabetes, diabetic ketoacidosis, or chronic weight management.

Ozempic offers a defined set of clinical benefits in adults with type 2 diabetes:

• Improved glycaemic control: Meaningful reductions in HbA1c that compare favourably with other glucose-lowering therapies.
• Weight reduction: Consistent loss of body weight during treatment, along with a reduction in systolic blood pressure and improvements in some lipid parameters.
• Reduced cardiovascular risk: In adults with established cardiovascular disease, Ozempic reduces the composite risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
• Kidney protection: Ozempic may reduce the risk of kidney failure and cardiovascular death in people with type 2 diabetes and chronic kidney disease.
• Convenient dosing: The once-weekly schedule is easier to maintain than daily injectables, and the pre-filled pen supports self-administration.

Ozempic is injected subcutaneously once weekly, on the same day each week, at any time of day, with or without food. The injection is given in the abdomen, thigh, or upper arm, with rotation of sites at each dose. Treatment may begin at 0.25 mg once weekly for four weeks to improve gastrointestinal tolerability and may not be effective for glycaemic control. After four weeks, the dose may be increased to 0.5 mg once weekly. If further glycaemic control is needed after at least another four weeks, the dose may be increased to 1 mg, and subsequently to a maximum of 2 mg once weekly, with each escalation following at least four weeks on the previous dose. Pens are refrigerated at 2°C to 8°C before first use; once in use, they may be kept at room temperature below 30°C or refrigerated for a limited period.

NOTE: The dosage for each person varies based on their weight, desired outcome, and current health status. One must never self-administer this medication unless recommended by one's doctor.

The most common side effects of Ozempic are gastrointestinal and are commonly experienced when the dose is increased. However, they diminish with time. These include:

• Gastrointestinal: Nausea, vomiting, diarrhoea, abdominal pain, constipation, low appetite, dyspepsia (indigestion), eructation (belching), and flatulence
• Injection-site reactions: Redness, itching, or discomfort at the injection site
• General: Fatigue, headache, and dizziness

Serious reactions that may require immediate medical attention:

• Acute pancreatitis: Presents as severe, persistent abdominal pain that may radiate to the back.
• Acute gallbladder disease: Including gallstones and cholecystitis, particularly with rapid or substantial weight loss.
• Hypoglycaemia: Uncommon with Ozempic alone, but may occur when combined with insulin or sulfonylureas.
• Acute kidney injury: Generally, in the context of dehydration from gastrointestinal effects.
• Hypersensitivity reactions: Anaphylaxis and angioedema are rare but possible.
• Worsening of diabetic retinopathy: Observed during rapid glycaemic improvement.
• Pulmonary aspiration: Reported in patients undergoing procedures with sedation or general anaesthesia.

Ozempic carries a boxed warning regarding the risk of thyroid C-cell tumours observed in rodent studies; the human relevance has not been established.

Contraindications

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Prior serious hypersensitivity reaction to semaglutide
• Pregnancy or if planning for pregnancy (discontinue at least two months before a planned pregnancy)

Use with caution

• History of pancreatitis (discontinue if there is a risk)
• Severe gastrointestinal disease or gastroparesis
• Diabetic retinopathy
• Renal impairment

• Planning on undergoing elective procedures with sedation or general anaesthesia (Ozempic can delay gastric emptying, increasing the risk of pulmonary aspiration)

Drug interactions

• Insulin (SEVERE): Risk of hypoglycaemia (low blood sugar levels). Insulin dose reductions may be required when the treatment is started.

• Sulfonylureas (SEVERE): Increased hypoglycaemia risk; dose reduction often necessary.
• Other semaglutide-containing products or GLP-1 receptor agonists (SEVERE): No added efficacy and raised adverse-effect risk; must not be combined.
• Warfarin, levothyroxine, and other narrow-therapeutic-index oral medications (CAUTION): Absorption may be altered by delayed gastric emptying; monitor clinical effect or relevant laboratory values.

Habits & missed doses

• While there is no specific food restriction, large or high-fat meals can worsen nausea when the dose is being increased. Eat smaller portions slowly to avoid it.
• Alcohol may increase the risk of pancreatitis and worsen gastrointestinal effects.
• If a dose is missed and the next scheduled dose is more than two days away, take the missed dose as soon as possible.
• If less than two days remain, skip the missed dose and take the next one on the regular day.
• Two doses should never be taken on the same day.

Overdose

Overdose may result in prolonged severe gastrointestinal symptoms. The treatment may include supportive care with attention to hydration. However, symptoms may persist for several days, given the long half-life of semaglutide. In such cases, patients should seek emergency care.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf https://www.ncbi.nlm.nih.gov/books/NBK603723/ https://medlineplus.gov/druginfo/meds/a618008.html https://www.ncbi.nlm.nih.gov/books/NBK501922/ https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 https://www.nejm.org/doi/full/10.1056/NEJMoa2403347